ITGB3 and cancer: According to analysis leveraging ROC Plotter (https://www.rocplot.com/immune [57]),, the ITGAV/ITGB3 and ITGAV/ITGB5 signatures in pretreatment biopsies were significantly higher in non-responders than in responders to ICI immunotherapy in various types of cancers (Fig. 6H).